A series of monosaccharides containing a biguanide functionality was prepared and evaluated for hypoglycemic activity. Among the analogues prepared were those involving D-glucose substituted on the 6- or 1-position (19 and 24), D-galactose substituted on the 6-position (7), and D-arabinose (31). The target compounds were evaluated in a modified rat glucose-tolerance test (oral glucose load/oral drug
制备了一系列含有双胍官能团的
单糖,并评估了其降血糖活性。在制备的类似物中,包括在6-或1-位上被取代的
D-葡萄糖(19和24),在6-位上被取代的
D-半乳糖(7)和
D-阿拉伯糖(31)的类似物。在改良的大鼠
葡萄糖耐量试验(
口服葡萄糖负荷/口服药物,100 mg / kg)中评估目标化合物。化合物8 [6-双胍基-1,2:3,5-双-O-(1-甲基亚乙基)-6-脱氧-α-
D-葡糖呋喃糖]和23 [甲基6-双胍基-6-脱氧-2, [3,4-O-三苄基-α-
D-吡喃葡萄糖苷]的活性最高,通过抑制血糖上升来衡量,其降血糖活性与苯乙双胍(1)和
二甲双胍(2)几乎相同。 。化合物31的活性稍差,抑制率为26%,